Instrument | Year | Population | Theoretical/conceptual framework | Constructs assessed | Items | Timing | Sample questions |
---|---|---|---|---|---|---|---|
DelibeRATE | 2012 | Set within three different parent RCTs: two surgical and one drug, all phase III pragmatic RCTs of direct head-to-head comparisons | Structured around a conceptual framework informed by theories of decision-making which separates decision-making process into deliberation and determination | 1. Information search | 10 items | Measured before consent to participate in trial | I understand the option, of participating in the trial or not, is available to me |
2. Knowledge gain | |||||||
3. Appraisal of knowledge sufficiency | |||||||
4. Imagining counterfactuals | |||||||
I know how I feel about participating in the trial or not | |||||||
5. Affective forecasting | |||||||
6. Preference construction | |||||||
Quality of Informed Consent (QuIC) [6] | 2001 | Patients and parents of paediatric patients enrolled in phase I, II or III clinical trial; tool developed with intention to be used across clinical areas | Conceptual framework considered: existing theoretical work on therapeutic misconception, regulations governing research, recommendations of National Cancer Institute working group | 1. Objective understanding (part A) | Total = 34 items | After consent | I have been informed how long my participation in this clinical trial is likely to last (part A) |
Part A: Objective understanding (n = 20) | |||||||
2. Subjective understanding (part B) | |||||||
Based on 13 domains identified in regulatory documents on informed consent | Part B: Subjective understanding (n = 14) | ||||||
The fact that your treatment involves research (part B) | |||||||
Informed Consent Assessment Instrument (ICAI) [9] | 2013 | Set within an open-drug RCT for tuberculosis | No explicit theory reported | Content informed by the four principles of research ethics: autonomy, beneficence nonmaleficence and justice | Total = 10 items | Measured right after time of consent, then remeasured 8 to 10 weeks after consent | Are you participating in a clinical trial? |
Authors state informed by principles of research ethics | |||||||
Are the risks and benefits of taking part in the study clear? | |||||||
Format informed by QuIC | |||||||
Brief Informed Consent Evaluation protocol (BICEP) [10] | 2005 | Set within eight different parent RCTs | No explicit theory reported; conceptual dimensions: therapeutic misunderstanding, voluntariness and understanding | Autonomous authorisation | Total = 15 items | Measured immediately after consent process | What is the primary purpose of [parent study]? |
Informed consent aggregate score (ICAS) (n = 10) | |||||||
What are the benefits to you of participating in the [parent study]? | |||||||
Therapeutic misconception aggregate score (TMAS) (n = 5) |